Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma - Horwitz, S. M., Koch, R., Porcu, P., Oki, Y., Moskowitz, A., Perez, M., Myskowski, P., Officer, A., Jaffe, J. D., Morrow, S. N., Allen, K., Douglas, M., Stern, H., Sweeney, J., Kelly, P., Kelly, V., Aster, J. C., Weaver, D., Foss, F. M., Weinstock, D. M. (American Society of Hematology (ASH), 2018)
6172213